Quick Answer
Entrada Therapeutics, Inc. reported Net Income Loss of -$143.75 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -319.0% in Net Income Loss from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$4.69 million | Q2 2020: -$6.17 million | Q3 2020: -$6.99 million | Q1 2021: -$8.38 million | Q2 2021: -$9.90 million | Q3 2021: -$14.43 million | Q1 2022: -$21.67 million | Q2 2022: -$23.18 million | Q3 2022: -$25.14 million | Q1 2023: -$6.67 million | Q2 2023: -$25.93 million | Q3 2023: $35.46 million | Q1 2024: $23.50 million | Q2 2024: $55.03 million | Q3 2024: -$14.03 million | Q1 2025: -$17.35 million | Q2 2025: -$43.10 million | Q3 2025: -$44.13 million.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Net Income Loss has declined by 442.0%.
- Historical annual values: Fiscal year 2025: -$143.75 million | Fiscal year 2024: $65.63 million | Fiscal year 2023: -$6.69 million | Fiscal year 2022: -$94.62 million | Fiscal year 2021: -$51.16 million | Fiscal year 2020: -$26.52 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: